Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Biodexa Pharmaceuticals ( (BDRX) ) is now available.
On February 10, 2025, Biodexa Pharmaceuticals announced that the US FDA granted Fast Track designation for eRapa, an encapsulated form of rapamycin, for treating familial adenomatous polyposis (FAP). This designation aims to expedite the drug’s development and review, addressing a critical need to delay or prevent surgical removal of the colon or rectum in FAP patients. The Phase 2 study demonstrated that eRapa is safe and reduces polyp burden, with plans for a Phase 3 study. This development reinforces the company’s position in addressing unmet medical needs and potentially impacts the therapeutic landscape for FAP.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing a pipeline of innovative products for treating diseases with unmet medical needs. Their lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer indications. The company is supported by proprietary drug delivery technologies and is headquartered in Cardiff, UK.
YTD Price Performance: -0.49%
Average Trading Volume: 138,805
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.72M
For a thorough assessment of BDRX stock, go to TipRanks’ Stock Analysis page.
